Boji Medical Technology Co.,Ltd. (SHE:300404)
China · Delayed Price · Currency is CNY 10.70
+0.08 (0.75%)
At close: Feb 12, 2026
Boji Medical Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 752.09 | 723.92 | 541.59 | 411.06 | 314.65 | 257.15 |
Other Revenue | 18.1 | 18.1 | 14.24 | 12.62 | 9.55 | 3.32 |
| 770.19 | 742.02 | 555.83 | 423.68 | 324.2 | 260.47 | |
Revenue Growth (YoY) | 2.26% | 33.50% | 31.19% | 30.69% | 24.47% | 16.25% |
Cost of Revenue | 556.69 | 517.98 | 373.34 | 267.57 | 185.56 | 148.54 |
Gross Profit | 213.5 | 224.04 | 182.49 | 156.11 | 138.64 | 111.93 |
Selling, General & Admin | 125.97 | 124.44 | 108.99 | 88.65 | 71.19 | 56.07 |
Research & Development | 57.07 | 62.59 | 54.97 | 43.68 | 27.65 | 26.44 |
Other Operating Expenses | 7.45 | 6.62 | 3.24 | 2.8 | 2.27 | 1.68 |
Operating Expenses | 212.62 | 214.03 | 182.56 | 150.05 | 109.43 | 94.87 |
Operating Income | 0.88 | 10 | -0.07 | 6.06 | 29.22 | 17.06 |
Interest Expense | -1.88 | -3.19 | -1.53 | -0.7 | -1.41 | -1.48 |
Interest & Investment Income | 1.84 | 4.28 | 4.33 | 3.64 | 4.21 | 3.33 |
Currency Exchange Gain (Loss) | 0 | 0 | -0.01 | -0.01 | -0.01 | 0.01 |
Other Non Operating Income (Expenses) | -2.28 | -2.34 | -0.59 | -0.41 | -0.4 | 0.29 |
EBT Excluding Unusual Items | -1.44 | 8.76 | 2.12 | 8.58 | 31.61 | 19.21 |
Gain (Loss) on Sale of Investments | 1.39 | 1.06 | 0.59 | 1.79 | - | - |
Gain (Loss) on Sale of Assets | -0.22 | -0.21 | 0 | - | - | - |
Asset Writedown | -2.76 | -0.08 | -0.03 | -0.07 | -0.3 | - |
Other Unusual Items | 8.61 | 8.89 | 14.95 | 14.27 | 15.78 | 8.56 |
Pretax Income | 5.59 | 18.42 | 17.63 | 24.57 | 47.09 | 27.77 |
Income Tax Expense | -3.58 | -12.24 | -9.56 | -4.74 | 3.59 | 2.9 |
Earnings From Continuing Operations | 9.16 | 30.66 | 27.19 | 29.31 | 43.5 | 24.87 |
Minority Interest in Earnings | -1.75 | -1.88 | -2.85 | -1.64 | -4.62 | -7.88 |
Net Income | 7.41 | 28.78 | 24.34 | 27.67 | 38.88 | 16.99 |
Net Income to Common | 7.41 | 28.78 | 24.34 | 27.67 | 38.88 | 16.99 |
Net Income Growth | -83.38% | 18.23% | -12.04% | -28.84% | 128.87% | 157.69% |
Shares Outstanding (Basic) | 384 | 382 | 370 | 367 | 349 | 317 |
Shares Outstanding (Diluted) | 384 | 383 | 371 | 367 | 349 | 318 |
Shares Change (YoY) | 0.70% | 3.14% | 0.97% | 5.18% | 10.02% | -0.29% |
EPS (Basic) | 0.02 | 0.08 | 0.07 | 0.08 | 0.11 | 0.05 |
EPS (Diluted) | 0.02 | 0.08 | 0.07 | 0.08 | 0.11 | 0.05 |
EPS Growth | -83.49% | 14.63% | -12.88% | -32.34% | 108.04% | 158.45% |
Free Cash Flow | 31.66 | -2.57 | -26.24 | -89.59 | -23.89 | 65.64 |
Free Cash Flow Per Share | 0.08 | -0.01 | -0.07 | -0.24 | -0.07 | 0.21 |
Dividend Per Share | 0.012 | 0.012 | 0.010 | 0.010 | 0.014 | - |
Dividend Growth | 20.00% | 20.00% | - | -30.07% | - | - |
Gross Margin | 27.72% | 30.19% | 32.83% | 36.85% | 42.77% | 42.97% |
Operating Margin | 0.11% | 1.35% | -0.01% | 1.43% | 9.01% | 6.55% |
Profit Margin | 0.96% | 3.88% | 4.38% | 6.53% | 11.99% | 6.52% |
Free Cash Flow Margin | 4.11% | -0.35% | -4.72% | -21.15% | -7.37% | 25.20% |
EBITDA | 27.65 | 34.07 | 20.4 | 24.99 | 46.03 | 32.05 |
EBITDA Margin | 3.59% | 4.59% | 3.67% | 5.90% | 14.20% | 12.31% |
D&A For EBITDA | 26.77 | 24.07 | 20.47 | 18.93 | 16.81 | 15 |
EBIT | 0.88 | 10 | -0.07 | 6.06 | 29.22 | 17.06 |
EBIT Margin | 0.11% | 1.35% | -0.01% | 1.43% | 9.01% | 6.55% |
Effective Tax Rate | - | - | - | - | 7.62% | 10.45% |
Revenue as Reported | 770.19 | 742.02 | 555.83 | 423.68 | 324.2 | 260.47 |
Advertising Expenses | - | 2.29 | 1.85 | 0.71 | 0.65 | 0.2 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.